CardioTech signs agreement for CardioPass European clinical trial

By Elaine Rigoli

Tampa, Fla., Aug. 10 - CardioTech International, Inc. said that it has signed an agreement with an investigator for the European clinical trial of its CardioPass synthetic coronary artery bypass graft.

"We are pleased with our selection of a principal investigator who has participated in a wide range of cardiovascular clinical trials. This decision fits within our planned timeline and is an important benchmark in the commencement and completion of the clinical trial," chief executive officer Michael Adams said in a news release.

CardioTech has hired a European-based contract research organization to assist in the organization, execution and completion of the clinical trial in the European Union. As previously announced, the company is moving forward with its approved protocol to conduct a limited clinical trial of 10 patients with a post-operative follow up period of 90 days.

CardioTech is a medical-device company based in Wilmington, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.